Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Devine

Showing results (511-520 of 577) with videos related to

Pageof 58
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
JAMA Neurology|December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim reportRichard A Nash, George J Hutton, Michael K Racke, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
The EMBO Journal|April 7, 2026
Global analysis of cancer cell responses to USP9X inhibitionPhilipp Schenk, Shane M Devine, Simon A Cobbold, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
Pageof 58

Showing results (511-520 of 577) with videos related to

Sort By:
Pageof 58
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
JAMA Neurology|December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim reportRichard A Nash, George J Hutton, Michael K Racke, et al.
Blood Advances|October 6, 2025
Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamideDipenkumar Modi, Yosra M Aljawai, Todd E DeFor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsBrian C Shaffer, Mahasweta Gooptu, Todd E DeFor, et al.
The EMBO Journal|April 7, 2026
Global analysis of cancer cell responses to USP9X inhibitionPhilipp Schenk, Shane M Devine, Simon A Cobbold, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
Pageof 58